Cellectis is a clinical-stage biotechnology company specializing in immuno-oncology. It develops allogeneic T-cell therapies using gene-editing technologies, focusing on chimeric antigen receptor (CAR) T-cells targeting various cancers.
Cellartis AB is a Swedish/British biotechnology company focused on pluripotent stem cells and technology for drug discovery research, toxicity testing and regenerative medicine
Since 2001, Cellartis has worked globally with industry and academia, platform providers and end users to develop the next generation of advanced stem cell products and technologies. The company leverages a deep experience in stem cell handling, scale up and differentiation into mature and functional human cells. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools today.
Cyto Pulse Sciences
Acquisition in 2010
Cyto Pulse Sciences is a biomedical device and treatment development company. It develops electric field based devices for production of DNA therapeutic vaccines, delivery of DNA vaccines, modification of cell genomes to correct genetic defects, production of hybridoma cell vaccines by fusing immune system cells and tumor cells, and the production of hybridomas used to produce monoclonal antibodies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.